# US 2015/0105558 A1 · R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and l-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105558 A1
- Document ID: US20150105558A1
- Status: Published application
- Kind: A1
- Application number: 14/574,935
- Filed: 2014-12-18
- Published: 2015-04-16
- Earliest claimed: 2009-07-27
- Assignees: Arimed Inc.
- Applicants: Arimed, Inc.
- Inventors: Dong Rack CHOI; Jin YANG; Sue Hye YOON; Sung Jae PYUN; Seung Hwan KIM; Seung Kyoo SEONG; Jei Man RYU
- Web page: https://patentgrep.com/patent/US20150105558A1

## CPC

- C07D 215/56: with oxygen atoms in position 4
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/145: {with organic compounds}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/4858: {Organic compounds}
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- C07C 229/24: having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 498/06: Peri-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Disclosed herein are R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial. Because the R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt is more soluble and less toxic and has less side effects as an antimicrobial agent than hydrochloride and the other salts (D-aspartate and phosphate) conventionally used, the salt may be useful for oral and injectable administration.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A method for preparing L-aspartate of a quinolone antimicrobial agent, comprising reacting the quinolone antimicrobial agent with L-aspartic acid in an inert organic solvent.

### Claim 12 (depends on 11)

The method of claim 11, Provided that the inert organic solvent is selected from the group consisting of ethyl acetate, methanol, ethanol, isopropanol, acetone, acetonitrile, hexane, isopropyl ether, water, and combinations thereof.

### Claim 13 (depends on 11)

The method of claim 11, provided that about 0.9 to 2.5 equivalent weight of the L-aspartic acid is added to about 1 equivalent weight of the quinolone antimicrobial agent.

### Claim 14 (depends on 11)

The method of claim 11, provided that the quinolone antimicrobial agent is active against Gram-positive bacteria, Gram-negative bacteria, or methicillin resistant bacteria.

### Claim 15

A method of improving water solubility of a quinolone antimicrobial agent, comprising converting the quinolone antimicrobial agent into a pharmaceutically acceptable L-aspartate salt.

### Claim 16 (depends on 15)

The method of claim 15, provided that the salt has water solubility of at least about 100 mg/ml at room temperature.

### Claim 17 (depends on 15)

The pharmaceutically acceptable salt of claim 15, provided that the salt has water solubility of at least about 118 mg/ml at room temperature.

### Claim 18 (depends on 15)

The method of claim 15, provided that the salt has a greater mean oral bioavailability than a hydrochloric acid salt of the quinolone antimicrobial agent.

### Claim 19 (depends on 18)

The method of claim 18, provided that the salt has at least about a 30% greater mean oral bioavailability than a hydrochloric acid of the quinolone antimicrobial agent.

### Claim 20 (depends on 15)

The method of claim 15, provided that the quinolone antimicrobial agent is active against Gram-positive bacteria, Gram-negative bacteria, or methicillin resistant bacteria.
